Albany, NY -- (SBWIRE) -- 08/22/2018 -- Aneurysmal Subarachnoid Hemorrhage (SAH) is defined as a condition where a brain aneurysm ruptures and causes bleeding into the compartment surrounding the brain, the subarachnoid space as per definition given by Brain Aneurysm Foundation. Often the aneurysm heals over, bleeding stops, and the person survives. In more serious cases, the bleeding may cause brain damage with paralysis or coma. In the most severe cases, the bleeding leads to death. Aneurysmal subarachnoid hemorrhage (SAH) is more common in women than in men as estimated by De Marchis GM et.al. 2017. Subarachnoid hemorrhage (SAH) is a common and frequently devastating condition, accounting for around 5% of all strokes.

According to the report of DelveInsight "Aneurysmal Subarachnoid Hemorrhage (SAH) Market Insights, Epidemiology and Market Forecast- 2027" Aneurysmal subarachnoid hemorrhage (aSAH) is a form of hemorrhagic stroke that affects up to 30,000 individuals per year in the United States. The estimated worldwide incidence of SAH is 9/100,000 persons/years in 2015. There is one drug NYMALIZE (nimodipine) which is approved by the U.S. Food and Drug Administration (FDA)–used as calcium channel blockers for stabilizing the patient by repairing the cause of bleeding for the treatment of SAH. Anti-anxiety medications and pain killers are also used for relieving headaches and pressure in the skull. However, the therapeutic market of SAH mostly include therapies like Surgery, Aneurysm clipping, endovascular coiling, and craniotomy. The market size is expected to increase by the major drivers such as rising incident population, technological advancements and upcoming therapies, strategies such as mergers and acquisitions etc. However, there are few factors that hinder the market growth, such as limited FDA approved drugs, high therapy cost etc.

The report covers a descriptive overview of the Aneurysmal Subarachnoid Hemorrhage (SAH), explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the SAH disease and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for SAH is provided, along with assessment of the impact of new therapies that will have on the current treatment landscape. A detailed review of global historical and forecasted SAH market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global SAH market.

For sample pages:https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market-insight-epidemiology-and-market-forecast

Reasons to buy:

1.The report will help in developing business strategies by understanding trends shaping and driving the SAH market.
2.To understand the future market competition in the SAH market and Insight reviews of the key market drivers and barriers.
3.Identification of strong upcoming players in the SAH market will help in devising strategies that will help in getting ahead of competitors.
4.In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Companies Covered: Idorsia, Edge Therapeutics Inc And many others……………

Table of Contents

1. Report Introduction
2. Aneurysmal Subarachnoid Hemorrhage (SAH) Market Overview at a Glance
3. Disease Background and Overview: Aneurysmal Subarachnoid Hemorrhage (SAH)
4. Epidemiology and Patient Population
5. Epidemiology of Aneurysmal Subarachnoid Hemorrhage (SAH) by Countries
5.1. United States
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.5. France
5.6. Italy
5.7. Spain
5.8. United Kingdom
5.9. Japan
6. Current Treatment & Medical practices
7. Unmet Needs of the Aneurysmal Subarachnoid Hemorrhage (SAH)
8. Marketed Therapies
8.1. Drug A: Company 1
8.2. Drug B: Company 2
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Aneurysmal Subarachnoid Hemorrhage (SAH)
11.1. Drug C: Company 3
11.2. Drug D: Company 4
12. Aneurysmal Subarachnoid Hemorrhage (SAH) : 7MM Market Analysis
13. Aneurysmal Subarachnoid Hemorrhage (SAH) : Country-Wise Market Analysis
13.1. United States
13.2. EU-5
13.3. Japan
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer

*** For detailed TOC request for sample pages.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.